SALT LAKE CITY, UT--(MARKET WIRE)--Jun 11, 2007 -- Myriad Genetics, Inc. (NasdaqGS:MYGN - News) (www.myriad.com) announced today that it presented a mathematical comparison of a “Staggered Start” and a “Randomized Withdrawal” clinical trial design with a “Natural History Staggered Start” clinical trial design at the Alzheimer’s Association Prevention Conference held June 9 - 12, 2007, in Washington, D.C. The analysis demonstrates that the “Natural History Staggered Start” trial design currently being used in the Flurizan Phase 3 study can provide the same level of disease modification support as the cross-over trial designs, which are challenged by ethical concerns, dropout bias and complications.
